Table 1.
Selected publications on the use of electrochemotherapy (ECT) in the treatment of breast cancer metastasis to the skin and subcutaneous tissue
| Author, year [ref.] | Patients, n | Lesions, n | Drug/delivery route | ECT courses, n | Response to treatment, % |
Follow-up | LPFS | |||
|---|---|---|---|---|---|---|---|---|---|---|
| CR | PR | SD | PD | |||||||
| Skarlatos, 2011 [6] | 8 | BD | bleomycin i.v. or i.t. | 13 (avg 1.6) | 25 | 75 | 0 | 0 | 60 days | ND |
| Kreuter, 2014 [28] | 13 | BD | bleomycin i.v. | 20 (avg 1.5) | 7.7 | 38.5 | 15.4 | 38.5 | ND | ND |
| Cabula, 2015 [25] | 113 | 214 | bleomycin i.v. or i.t. | 113 (avg 1) | 58.4 | 31.8 | 7.1 | 1.8 | min. 8 weeks (avg 5.9 months) | 12-month LPFS 86.2%; in group with CR 96.4% |
| Campana, 2014 [29] | 55 | 212 | bleomycin i.v. or i.t. | ND (avg 2) | 40 | 47.3 | 12.7 | 0 | min. 8 weeks (avg 32 months) | 2-year LPFS < 70 years of age 93%; > 70 years 67% |
| Campana, 2012 [38] | 35 | 516 | bleomycin i.v. | 62 (avg 1.8) | 54.3 | 37.1 | 8.6 | 0 | min. 8 weeks (avg 32 months) | 36-month LPFS 81% |
| Matthiessen, 2012 [27] | 12 | 25 | bleomycin i.v. | 27 (avg 2.2) | 8 | 8 | 76 | 8 | min. 8 weeks (avg 11 weeks) | ND |
| Benavento, 2012 [26] | 12 | 142 | bleomycin i.v. | 16 (avg 1.3) | 75.3 | 17 | 7.7 | 0 | min. 4 weeks (avg 30 weeks) | ND |
| Wichtowski, 2016 [39] | 7 | 35 | bleomycin i.v. | 9 (avg 1.3) | 43 | 43 | 0 | 14 | min. 8 weeks (avg 12 weeks) | ND |
| Total/average | 255 | 1,454 | 39 | 37 | 16 | 8 | ||||
| OR = 76% | ||||||||||
CR = Complete response; PR = partial response; SD = stable disease; PD = progressive disease; LPFS = local progression-free survival; i.v. = intravenous; i.t. = intratumoral; min. = minimum; avg = average; ND = no data; OR = overall response.